Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04210037 |
|
Recruitment Status :
Terminated
(Sponsor decision)
First Posted : December 24, 2019
Last Update Posted : July 12, 2022
|
Sponsor:
Ascentage Pharma Group Inc.
Information provided by (Responsible Party):
Ascentage Pharma Group Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | August 30, 2021 |
| Actual Study Completion Date : | May 15, 2022 |